Published in Hepatitis Weekly, September 11th, 2000
Medical investigators in Taiwan have examined the effects of treating HBV patients with lamivudine for two years. Published results of their efforts were made available recently in the journal Gastroenterology.
A research team led by Y.F. Liaw randomized 334 patients to receive either daily lamivudine therapy or a placebo after having already receiving lamivudine for one year. Liaw et al. quantified serum markers for viral progression,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.